STENABOLIC (SR-9009) – Solution, 600mg (20mg/mL)STENABOLIC (SR 9009) SR9009, also known as Stenabolic, has been studied in mice and shown to increase running speed, reduce obesity levels, and boost mitochondrial production, thus enhancing muscle mass and metabolism. Although SR 9009 is often associated with Selective Androgen Receptor Modulators (SARMs), it functions via different pathways. It is actually a Rev ErbA agonista nuclear receptor reverse viral erythroblastosis oncogene product alpha

STENABOLIC (SR-9009)

SR9009, also known as Stenabolic, has been studied in mice and shown to increase running speed, reduce obesity levels, and boost mitochondrial production, thus enhancing muscle mass and metabolism.

Although SR-9009 is often associated with Selective Androgen Receptor Modulators (SARMs), it functions via different pathways. It is actually a Rev-ErbA agonist—a nuclear receptor reverse viral erythroblastosis oncogene product alpha agonist—found in the liver, skeletal muscles, and brain. It is most notable for its role in influencing circadian rhythms.

SR-9009 and Weight Loss

In a study conducted by Solt et al., mice were administered SR-9009 or saline injections twice a day while on a high-fat diet (comprising 60% fat and 20% carbohydrates). The study aimed to assess whether SR-9009 could aid weight loss in diet-induced obesity cases (source).

It was observed that due to the stress of bi-daily injections, both sets of mice lost body fat. However, mice treated with SR-9009 lost 60% more fat than those treated with saline injections. Additionally, substantial reductions were reported in plasma triglycerides (12%), total cholesterol (47%), plasma glucose levels (19%), leptin (80%), and inflammatory cytokines (72%) in the mice administered SR-9009 (source).

SR-9009 and Bone Density

In another intriguing study by Song et al., 12-week-old female mice were housed in a research laboratory under a strict 12-hour light and dark cycle and were provided with free access to food and water. Forty mice were divided into groups that either underwent full ovariectomy or a sham operation. After the procedure, the mice were injected with varying doses of SR-9009 (source).

Overall, the study's findings indicated that SR-9009 supplementation inhibited the differentiation of osteoclast formation in mice, suggesting reduced bone degradation. Furthermore, in female mice that underwent ovariectomy to simulate postmenopausal bone loss, supplementation with SR-9009 led to a greater number of bone trabeculae in the femur and tibia. The bone volume and tissue also increased by a factor of 1.550, 1.701, or 1.601 upon administering doses of 30, 50, or 100 mg/kg of SR-9009, respectively (source).

Concentration
20mg/ml.

Half Life
2.5 hours.

DISCLAIMER
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or domestic use. Please familiarize yourself with our DISCLAIMER before ordering.

Data Sheet

Stenabolic SR-9009 – Solution, 600mg (20mg/mL)